<DOC>
	<DOCNO>NCT00803088</DOCNO>
	<brief_summary>The objective multicenter , single-arm , open-label clinical study evaluate safety perform bronchial thermoplasty Alair® System two treatment session treat severe asthma .</brief_summary>
	<brief_title>Safety Bronchial Thermoplasty Performed With Alair® System During Two Treatment Sessions Treat Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Subject adult age 18 70 year . Subject able read , understand , sign write Informed Consent form participate Study . Subject asthma take maintenance asthma medication include : 1 . Inhaled corticosteroid ( ICS ) dosage ≥1000μg beclomethasone per day equivalent , AND long acting β2agonist ( LABA ) dosage ≥100μg per day Salmeterol equivalent . 2 . Other asthma medication leukotriene modifier , antiIgE , acceptable ( Subjects Xolair® must Xolair great 1 year ) . 3 . Oral corticosteroid ( OCS ) dosage , great , 10mg per day . Subject AQLQ score Baseline 6.25 less . Subject Prebronchodilator FEV1 great equal 60 % predicted medication stabilization Baseline Period . Subject PC20 &lt; 8mg/ml per methacholine inhalation test use standardize methods* . Subject least one day asthma symptom 2 week Baseline Diary Period . Subject nonsmoker 1 year great ( former smoker , less 10 pack year total smoking history ) . Subject able undergo bronchoscopy opinion Investigator per hospital guideline . Subject willing able comply Study protocol , attend followup visit , requirement take abstaining medication . Subject participate another clinical trial within 6 week Baseline Period involve respiratory intervention could affect outcome measure Study . Subject requirement Baseline Diary period rescue medication use prophylactic use exercise exceed average : 1 . 8 puff per day shortacting bronchodilator , 2 . 4 puff per day longacting rescue bronchodilator , 3 . 2 nebulizer treatment per day . Subject postbronchodilator FEV1 le 65 % predict . Subject three hospitalization exacerbation asthma prior 12 month . Subject recent history lifethreatening asthma , define least one intubation asthma within past five year . Subject ICU admission asthma within prior 24 month . Subject four infection low respiratory tract require antibiotic prior 12 month . Subject four asthma exacerbation require oral steroid pulse prior 12 month . Subject know sensitivity medication require perform bronchoscopy ( lidocaine , atropine , benzodiazepine , parasympathomimetic agent ) . Subject undergoing immunosuppressant therapy steroid ( e.g. , methotrexate ) . Subject use systemic betaadrenergic block agent . Subject insulindependent diabetic . Subject pregnant nursing mother , plan become pregnant within next 12 month . Subject respiratory disease include interstitial lung disease , emphysema , cystic fibrosis , vocal cord dysfunction , mechanical upper airway obstruction , ChurgStrauss syndrome , active allergic bronchopulmonary aspergillosis ( current total IgE &gt; 1000 Units/mL positive specific IgE aspergillus evidence central bronchiectasis ) . Subject significant segmental atelectasis , lobar consolidation , significant unstable pulmonary infiltrate , pneumothorax , confirm Xray . Subject chronic sinus disease define five episode sinusitis past 12 month , continuous symptom sinus infection ( purulent discharge ) significant change nasal steroid dosage last six week . Subject uncontrolled sleep apnea ( sleep apnea control either dental appliance continuous airway positive pressure ( CPAP ) ) . Subject uncontrolled gastroesophageal reflux disease define significant increase therapy last six week . Subject lung cancer history lung cancer . Subject currently active cancer history cancer le 5 year disease free survival time ( whether evidence local recurrence metastasis ) . Localized basal cell carcinoma ( without metastasis ) skin acceptable . ( Subject history cancer ( exclude lung cancer ) five year disease free survival time may include Study agreement Sponsor case case basis ) . Subject history epilepsy . Subject currently clinically significant cardiovascular neurovascular disease , include myocardial infarction congestive heart failure , angina , clinically significant cardiac dysrhythmia conduction defect , cardiomegaly , cardiomyopathy , aortic aneurysm , cerebral vascular disease , stroke . Subject anticoagulant therapy , bleed diathesis , platelet dysfunction , thrombocytopenia platelet count le 125,000/mm2 know coagulopathy ( INR &gt; 1.5 ) . Subject uncontrolled hypertension ( &gt; 200mm Hg systolic &gt; 100mm Hg diastolic pressure ) . Subject electrical stimulation device pacemaker , defibrillator , deep nerve deep brain stimulator . Subject psychiatric disorder judgment Investigator could interfere provision Informed Consent , completion test , therapy , followup visit . Subject medical condition Investigator 's opinion would make inappropriate Study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>